NOVO B arrived at its Q1 2026 results carrying a bruised chart and a sceptical market — and then blew the doors off estimates.
Q1 adjusted EPS came in at $1.04 against a consensus of $0.87. Sales reached $15.2 billion, far ahead of the $11.1 billion the Street had pencilled in. Full-year sales guidance was lifted to a range of $42.4–$46.2 billion from $40.5–$44.3 billion. The catalyst behind the upgrade was the commercial debut of a Wegovy pill — the oral formulation of semaglutide that investors had long flagged as a pivotal growth driver. Bloomberg also reported that generic Ozempic in China is now delayed until next year, removing a near-term competitive overhang. The stock closed up roughly 8% on the week at DKK 285.90, recovering ground lost over the prior months' selloff.
The borrow market tells a story of disengagement rather than pressure. Short interest is minimal at just 0.19% of free float — roughly flat with where it was a week ago and barely changed over the past month. Availability runs at nearly 7,000% of short interest, meaning the lending pool is essentially untouched. Cost to borrow has drifted lower, from around 1.6% in mid-April to 1.25% now — a multi-week low. None of these readings point to meaningful short-side conviction. Utilisation, at 1.44%, has edged up slightly in recent days but remains well below the 52-week peak of 3.45%. The borrow market, in short, reflects a stock where bears are largely absent.
The factor profile has its own points of interest. The dividend score ranks at the 83rd percentile, reflecting a consistent payout history, though the most recent dividend data is stale — the last recorded event dates to early 2022 and should not be taken as current. The EV/EBIT factor sits at the 78th percentile, suggesting the market is ascribing reasonable value relative to earnings power even after the week's re-rating. The PE multiple now stands at 13.7x, having expanded by roughly 2.4 points over the past 30 days as the stock recovered. The P/B ratio similarly re-rated, adding 0.7 points over the month to 5.3x. The ORTEX short score of 26.6 — in the bottom third of the universe — confirms what the raw data already suggests: there is no short-side pressure on this name. The available analyst price target data is nearly three years old and cannot be treated as current; no recent changes are on file.
Ownership is dominated by founding entity Novo Holdings, which holds 28.2% of shares and has not changed its position. Among external holders, Vanguard added roughly 6.2 million shares in Q1, and T. Rowe Price added 1.3 million. Both BlackRock and JP Morgan Asset Management also added modestly. Norges Bank Investment Management trimmed by 8.4 million shares over the same period. The insider record shows February sales by the CFO and Chief Scientific Officer — routine in character, set against a backdrop of award grants at similar prices, and carrying low significance scores. The net 90-day insider picture is modestly positive in share terms but offers no strong directional signal.
The March earnings event — a Q4 or annual release — produced a one-day move of -3.1%, with the stock essentially flat five days later. That prior print therefore provided no durable tailwind, leaving the Q1 beat as the first genuinely market-moving catalyst in several months. The next scheduled event is flagged for August 5, giving the Wegovy pill launch data roughly one quarter to accumulate before the Street re-examines growth trajectory and pricing dynamics in the US and European GLP-1 markets.
See the live data behind this article on ORTEX.
Open NOVO B on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
